Login / Signup

Pharmacometrics of high dose ivermectin in early COVID-19: an open label, randomized, controlled adaptive platform trial (PLATCOV).

William H K SchillingPodjanee JittamalaJames A WatsonManeerat EkkapongpisitTanaya SiripoonThundon NgamprasertchaiViravarn LuviraSasithorn PongwilaiCintia Valeria CruzJames John CallerySimon BoydVaraporn KruabkonthoThatsanun NgernsengJaruwan TubprasertMohammad Yazid AbdadNattaporn PiaraksaKanokon SuwannasinPongtorn HanboonkunupakarnBorimas HanboonkunupakarnSakol SookpromeKittiyod PoovorawanJanjira ThaipadungpanitStuart BlacksellMallika ImwongJoel TarningWalter R J TaylorVasin ChotivanichChunlanee SangketchonWiroj RuksakulKesinee ChotivanichMauro Martins TexeiraSasithon PukrittayakameeArjen M DondorpNicholas Philip John DayWatcharapong PiyaphaneeWeerapong PhumratanaprapinNicholas J Whitenull null
Published in: eLife (2023)
Clinical trial number: ClinicalTrials.gov (NCT05041907).
Keyphrases
  • phase iii
  • clinical trial
  • phase ii
  • high dose
  • double blind
  • open label
  • coronavirus disease
  • sars cov
  • placebo controlled
  • low dose
  • study protocol
  • stem cell transplantation
  • high throughput
  • randomized controlled trial